Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacovigilance01:19

Pharmacovigilance

1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

184
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
184
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

26
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
26

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Transfusion-Associated Graft-Versus-Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?

European journal of neurology·2026
Same author

Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom.

British journal of haematology·2026
Same author

Defining Activity-Based Subgroups in Multiple Sclerosis: A Review and Framework Proposal.

European journal of neurology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Multi-arm multi-stage platform trials for neurological disease: accelerating progress.

Lancet (London, England)·2026
Same author

Non-invasive biomarkers for Neurosarcoidosis: Complement activation as a tool for diagnosis and prognosis.

Journal of neuroimmunology·2026

相关实验视频

Updated: Sep 19, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

用纳塔利祖马布生物类似剂进行JCV测试的方法:英国的共识声明.

Ruth Dobson1, Tarunya Arun2, James Varley3

  • 1Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University London, UK; Department of Neurology, Royal London Hospital, Barts Health NHS Trust, UK.

Multiple sclerosis and related disorders
|June 3, 2025
PubMed
概括

纳塔利祖马布安全监测的JC病毒 (JCV) 血清测试显示Immunowell和Stratify测试之间的结果不一致. 这可能导致错误的渐进性多焦点白血脑病 (PML) 风险分类,影响患者获得治疗和医疗费用.

关键词:
生物类似的生物类似物这就是JC病毒.多发性硬化症是多发性硬化症.娜塔莉莎表示渐进性的多焦点白内障脑细胞病变.

更多相关视频

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

740
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.6K

相关实验视频

Last Updated: Sep 19, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

740
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.6K

科学领域:

  • 神经学 神经学
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 生物仿制药提供潜在的成本节约,并改善了对多发性硬化症的纳塔利祖马布等治疗方法的获取.
  • 对JC病毒 (JCV) 血清状况的测试对于在纳塔利祖马布治疗的患者中分层逐渐多焦点白血脑病 (PML) 风险至关重要.
  • 目前的风险分层依赖于Stratify试验,但Immunowell试验与生物类似物natalizumab,Tyruko.一起使用.

研究的目的:

  • 评估Immunowell和Stratify试验之间的JCV血清状况结果的一致性.
  • 评估不一致的结果对PML风险分类和患者管理的影响.
  • 为管理不同JCV检测结果的患者提供指导.

主要方法:

  • 从Immunowell和Stratify测定中获得的JCV血清状况结果的比较.
  • 分析不一致的结果,特别是在PML风险值附近.
  • 对患者监测和治疗决策的临床影响的评估.

主要成果:

  • 与Stratify测试相比,Immunowell测试似乎更有可能产生阳性JCV指数.
  • 负面结果显示Immunowell和Stratify之间的高度一致,支持合理的安全战略.
  • 不一致的结果可能会导致病人错误地对PML风险进行分类.

结论:

  • 不一致的JCV测试结果可能导致不适当的PML风险评估,可能会拒绝有效的纳塔利祖马布治疗或导致不必要的监测.
  • 需要指导来管理不一致的结果,平衡安全与患者获得治疗,并尽量减少医疗负担.
  • 协调JCV测试或为不一致的结果建立明确的协议对于治疗多发性硬化症的最佳患者护理至关重要.